My research area involves the study of the mechanisms of resistance to the first-line antituberculosis drugs such as isoniazid and pyrazinamide, as well as the identification and testing of new inhibitors against M. tuberculosis. We have shown that the main target of isoniazid is the enoyl-ACP reductase InhA, an essential gene of the fatty acid synthase type II system, deciphered the mechanisms of resistance to isoniazid caused by mutations in ndh encoding the NADH dehydrogenase, and identified a novel mechanism of INH and ETH resistance in M. tuberculosis (mutations in the mycothiol biosynthesis pathway). Screening of a commercially available chemical library led to the identification of 2 new compounds that are cidal against drug-susceptible and drug-resistant M. tuberculosis.
Lab Manager | firstname.lastname@example.org |
I have worked with Bill Jacobs for over 20 years, and currently act as the manager of his lab. I oversee and facilitate all the daily research-oriented activities of the Jacobs group. I am also responsible for coordinating the import/export of scientific materials that support our work. I run occasional targeted experiments for Dr. Jacobs. Acquiring and maintaining the supplies and equipment necessary for our studies is another key part of my role.
Director of BSL-3 Lab | email@example.com
I focus on new TB vaccine research and novel anti-tuberculosis agent development, use of animal models to investigate infections and pathogen-host interactions. I am responsible for the safe use of our Bio-Safety Level 3 facility at Einstein, including training and testing post-docs and students according to their own research projects. I also chair the regular meetings of the TB Research Group internal Biosafety Committee for TB research projects and coordinate protocols and resources for BSL3 experiments.
Research Technician | firstname.lastname@example.org |
Research Technician | email@example.com |
I’m a technician in the lab, providing technical support for PhD students, post-docs, and other lab staff. I mainly work on molecular cloning, phage packaging and high-titer phage preparation for specific gene deletions. Also, I carry out some routine laboratory tasks such as preparing specific agar plates which are commonly and largely used in the lab.
Research Technician | firstname.lastname@example.org |
My main responsibility is technical support for TB study using animal models in BSL3 facility. I perform IV, SQ, IP, aerosol infection of mouse; harvest and process organ/tissue/blood samples; provide gavage treatment. I also maintain transgenic/knockout mouse colonies. I help with bacterial phage work as well.
Senior Research Fellow | email@example.com
Tuberculosis is a dreadful disease. Success of M.tb lies in its survival in macrophages by evasion of host immune responses. Only available vaccine till now is BCG, and its efficacy varies with age and geographical distribution. Therefore, my overall goal is to develop better understanding of the host-pathogen interactions and utilize that to identify potential new drug targets or vaccine candidates. My focus is (1) Identification of novel mycobacterial factors involved in virulence and evasion of host immune responses (2) Understanding of metabolic pathways required for survival and persistence of mycobacteria in the host. I am using multiple techniques involving combination of molecular biology, biochemistry, genetics, metabolomics, cell biology and Immunology to answer these queries.
Pathogens have developed an arsenal of strategies to evade host immunity. My research interests lie in defining the mechanisms that either Mycobacterium tuberculosis or herpes simplex virus employ to circumvent detection and elimination by the host immune response. Additionally, I wish to define the immune components that provide the host with the best protection against these pathogens. By delineating both immune evasion strategies and the optimal immune response following either M.tb or HSV infection, I envision vaccines and therapeutic approaches can be developed to permit pathogen sterilization in the host.
Research Fellow | firstname.lastname@example.org
I am developing a recombinant TB vaccine using the HSV-2 ∆gD vaccine as a vector. This vaccine vector elicits potent immune responses including antibody-dependent cell-mediated killing, which may be the key to developing a TB vaccine effective against all forms of TB disease.
Research Fellow | email@example.com |
Mycobacterium tuberculosis (Mtb) persistence, marked by a subpopulation of cells that survive extensive antibiotic exposure without acquiring genetic drug resistance mutations, is a major impediment to treating tuberculosis (TB). Understanding the molecular mechanisms by which Mtb regulates this persistence phenotype is paramount to the design of novel anti-TB therapeutics. Employing a specialized transduction allele transfer method, precise null-deletions are being generated of various genes involved in the transcription initiation or amino acid biosynthesis pathways in virulent and biosafety level-2 Mtb strains. This research aims to investigate those effectors driving the antibiotic-induced persistence phenotype and may identify new drug target candidates for the improved treatment of TB.
Cristian Varela Ramirez
Research Fellow | firstname.lastname@example.org
Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis that remains as one of the main causes of deaths worldwide affecting primarily to underdeveloped and poor communities, where the diagnostic tools are not available and the right drug treatments cannot be implemented properly. Resistance to tuberculosis drugs is one the major barriers to effective treatment and the emergence of MDR-TB and XDR-TB requires quick, efficient and cheap diagnostic methods.
My research is mainly focused on the study of the biology of mycobacteriophages, using them as molecular tools in order to assess drug susceptibility and drug resistance. Currently I am developing an efficient and cheap point-of-care diagnostic test for detection of M. tuberculosis using a luminescent reporter in partnership with Global Good-Intellectual Ventures Laboratory.
Research Fellow | email@example.com
My research interests are human pathogens, their drug resistance mechanisms and pathogenesis. I have been working on developing Next-Generation Sequencing diagnostics pipeline for human pathogens to provide results in a time frame that would impact patient care. Additionally, I work on a project to make a point of care drug susceptibility test for Mycobacterium tuberculosis and other human pathogens using next-generation luciferase reporter phages.
MD/PhD Student | firstname.lastname@example.org
Vaccines prevent millions of deaths per year, but the current recommended immunization schedule only covers a handful of diseases. While a seasonal vaccine is available for influenza, this vaccine has limited protection against known strains of influenza and no protection against emergent, pandemic strains. By expressing the genes from divergent strains of influenza, I am using the HSV ΔgD-2 vector to generate a protective immune response against influenza challenge. We believe that the optimal HSV ΔgD-2 recombinant vector could lead to a universal influenza vaccine.
Research Trainee | email@example.com
I'm a research trainee in the Jacobs lab and recently graduated from Mount Saint Mary College as a chemistry major. I have a strong interest in virology and currently work on three projects related to the field. My main project involves aiding in the elucidation of the immunological mechanism behind ΔgD-HSV vaccine. I am also interested in developing nanopore sequencing protocols for HSV and mycobacteriophage. Since most of my undergraduate research is involved in bacteriophage biology, I assist the training of high school and college students in isolating novel bacteriophage.
Research Trainee | firstname.lastname@example.org
I am participating in projects involving the candidate herpes vaccine, ΔgD-2, which is an HSV-2 virus deleted in glycoprotein D (gD), a glycoprotein essential for viral entry. My primary role is to construct various cell lines, which will stably express herpes antigens. I am currently constructing a gD-expressing Vero cell line according to good manufacturing practices, which will ultimately be used to complement the ΔgD-2 vaccine.
Medical Fellow | email@example.com
My research uses recombinant HSV viruses to study antibody-dependent cell-cytotoxicity (ADCC). I also create viruses that harness ADCC for broadly protective vaccines against Influenza, HIV, and other pathogens. ADCC occurs when our bodies make antibodies against pathogens which act like calling cards for immune cells. Immune cells recognize these antibodies and kill the infected cells. ADCC is an often-forgotten arm of the immune system, but I believe it holds the key to curing a broad array of disease.
Research Coordinator | firstname.lastname@example.org
I recently graduated from the Mayo Clinic with a M.S. in Molecular Pharmacology and Experimental Therapeutics. In addition, I have a BS in Microbiology/Cell and Molecular Biology with an emphasis in microbial pathogenesis. My research interests stem from infectious diseases to regenerative medicine.